Page 179 - ESHRE2019

References
Silver AJ, Larson JL, Silver MJ, Lim RM, Borroto C, Spurrier B, et al. Carrier screening is a deficient strategy for determining sperm donor eligibility and reducing risk of disease in recipient children. Genet Test Mol Biomarkers 2016;20:276–84.
Abulí A, Boada M, Rodríguez‐Santiago B, Coroleu B, Veiga A, Armengol L, et al. NGS‐based assay for the identification of individuals carrying recessive genetic mutations in reproductive medicine. Hum Mutat 2016;37:516–23.
Green RC, Berg JS, Grody WW, Lalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565–74.
Baker VL, Rone HM, Adamson GD. Genetic evaluation of oocyte donors: recipient couple preferences and outcome of testing. Fertil Steril 2008;90:2091–8.
Ioannou L, Massie J, Lewis S, Petrou V, Gason A, Metcalfe S, et al. Evaluation of a multi‐disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet 2010;78:21–31.
References
Jackson E, Edwards J, Besser A, Isley LJ. Recipients' perspectives regarding expanded carrier screening of gamete donors. Fertil Steril 2017;108(3 Suppl):e265–6.
Dondorp W, De Wert G, Pennings G, Shenfield F, Devroey P, Tarlatzis B, et al. ESHRE Task Force on Ethics and Law 21: genetic screening of gamete donors: ethical issues. Hum Reprod 2014;29:1353– 9.
Callum P, Messiaen LM, Bower PV, Skovby F, Iger J, Timshel S, et al. Gonosomal mosaicism for an NF1 deletion in a sperm donor: evidence of the need for coordinated, long‐term communication of health information among relevant parties. Hum Reprod 2012;27:1223–6.
Jellis CL, Desai MY. Hypertrophic cardiomyopathy: still connecting the dots between genotype and phenotype. Cardiovasc Diagn Ther 2015;5:156.
Stevens B, Krstic N, Jones M, Murphy L, Hoskovec J. Finding middle ground in constructing a clinically useful expanded carrier screening panel. Obstet Gynecol 2017;130:279284.
20
19
173
PRECONGRESS COURSE 01 I VIENNA, AUSTRIA – 23 JUNE 2019 177